Defense Advanced Research Projects Agency, or DARPA, has awarded the Company a technology development contract worth up to $3.8 million over five years as part of its Dialysis-Like Therapeutics (DLT) program to treat sepsis, pending satisfactory achievement of key milestones.
IMMUNE Pharmaceuticals is an Israeli and US based emerging leader in the development of antibody therapeutics in cancer and inflammation. IMMUNE has multiple drug candidates based on proprietary cytotoxic formulations, linkers and monoclonal antibodies.
How can one optimally design a clinical trial program for a medical device for a FDA clearance/approval submission? OneMedRadio spoke with Dr. Vladimir Dragalin and Dr. Michael Feldstein of Aptiv Solutions to discuss the changing tides of medical device regulatory and the advantages of using an adaptive design trial.
Christine Jacobs, CEO of Theragenics, enlightened OneMedForum NY 2012 attendees on a categorical operational observation: while the number of employees represent a fair barometer of her company’s success, they also define her compliance costs. Jacobs and David Weild, former NASDAQ Vice Chair, discussed the evolving market landscape with the passing of the JOBS Act.
August 06-08, 2012 · The Westin San Francisco Market Street · San Francisco, CA A new paradigm in drug and diagnostic development is emerging. Exciting […]
OneMedPlace has announced that Christine Jacobs, Co-Chair to the SEC Advisory Board on Small and Emerging companies, will discuss efforts by the SEC to address the challenges faced by small public companies.
BiognoSYS, a Swiss leader and founder of proteomics in the Greater Zurich Area, is developing targeted proteomics based on a novel mass spectrometric technology.
OneMedForum NY 2012 to be held tomorrow, July 12 stands to be a huge success. The third annual OneMedForum NY opens with a reception on […]
The Securities and Exchange Commission missed a deadline of July 4, 2012 to adopt rules lifting a general advertising ban for private securities offerings as a part of the JOBs Act.
Delenex Therapeutics, a Swiss biotech in the Greater Zurich Area is developing antibodies to treat serious medical conditions with high unmet need.
Copyright © 2024 | WordPress Theme by MH Themes